NuCana PLC (NCNA) Shares Sold by Partner Fund Management L.P.

Partner Fund Management L.P. cut its holdings in shares of NuCana PLC (NASDAQ:NCNA) by 7.4% in the third quarter, HoldingsChannel.com reports. The firm owned 389,358 shares of the company’s stock after selling 31,209 shares during the quarter. Partner Fund Management L.P.’s holdings in NuCana were worth $9,703,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in NCNA. Baillie Gifford & Co. grew its holdings in shares of NuCana by 26.2% during the 3rd quarter. Baillie Gifford & Co. now owns 827,308 shares of the company’s stock worth $20,617,000 after purchasing an additional 171,858 shares during the period. Woodford Investment Management Ltd grew its holdings in shares of NuCana by 27.3% during the 2nd quarter. Woodford Investment Management Ltd now owns 420,000 shares of the company’s stock worth $7,980,000 after purchasing an additional 90,000 shares during the period. Alliancebernstein L.P. grew its holdings in shares of NuCana by 16.7% during the 3rd quarter. Alliancebernstein L.P. now owns 543,049 shares of the company’s stock worth $13,533,000 after purchasing an additional 77,519 shares during the period. Asymmetry Capital Management L.P. grew its holdings in shares of NuCana by 82.4% during the 3rd quarter. Asymmetry Capital Management L.P. now owns 87,321 shares of the company’s stock worth $2,176,000 after purchasing an additional 39,449 shares during the period. Finally, Alps Advisors Inc. grew its holdings in shares of NuCana by 21.9% during the 3rd quarter. Alps Advisors Inc. now owns 56,419 shares of the company’s stock worth $1,406,000 after purchasing an additional 10,150 shares during the period. Institutional investors and hedge funds own 25.29% of the company’s stock.

A number of equities analysts have recently weighed in on NCNA shares. Zacks Investment Research upgraded NuCana from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Thursday, October 4th. ValuEngine upgraded NuCana from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Cowen reiterated a “buy” rating on shares of NuCana in a report on Wednesday, August 29th. Finally, Piper Jaffray Companies started coverage on NuCana in a report on Thursday, October 18th. They set an “overweight” rating and a $36.00 price target for the company.

Shares of NuCana stock opened at $17.00 on Thursday. NuCana PLC has a 12 month low of $9.32 and a 12 month high of $32.00. The stock has a market cap of $551.29 million, a P/E ratio of -16.04 and a beta of 7.70.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2018/12/06/nucana-plc-ncna-shares-sold-by-partner-fund-management-l-p.html.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.

See Also: Average Daily Trade Volume – What You Need to Know

Want to see what other hedge funds are holding NCNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuCana PLC (NASDAQ:NCNA).

Institutional Ownership by Quarter for NuCana (NASDAQ:NCNA)

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply